FDA to Review Saxagliptin for Possible Heart Failure Risk More to come in next week’s issue.

Cyanidin and delphinidin, when encapsulated in nanoliposoms, decrease in vitro glycation of albumin and hemoglobin A. They also decrease blood glucose and blood cholesterol in diabetic mice. Iranian researchers investigated the effects of these materials in two forms of free and nanoliposomal on decreasing the damages caused by diabetes. Planta …

Oramed has submitted a protocol to the FDA to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The double-blind, randomized, placebo controlled, seven-day study design will be carried out at an inpatient setting on twenty-four type 1 diabetic patients. It’s hope …

America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development — all either in clinical trials or under review by the FDA — include 30 for type 1 diabetes, 100 for type 2 and 52 …

For both healthy patients and those with metabolic impairment, risk decreased when participants took the recommended daily allowance of magnesium….

Brain activity in region responsible for food anticipation increased while exercising upon exposure to healthy food as opposed to unhealthy alternative….

JDRF announces funding of $7 million to help ensure a rapid transition of ViaCyte’s VC-01 encapsulated cell therapy product into the clinical phase of development….

Prediction algorithms could provide the key….  

Replacing snacks with low-fat yogurt can cut risk nearly in half….

Noninvasive capilaroscopy, laser Doppler flowmetry, and retinal imaging among techniques used….